Semaglutide is a GLP-1 receptor agonist that is formulated for oral administration as Rybelsus®.
Simulations Plus Invests in Clinical Development Technology Company Nurocor
Investment to accelerate innovations in biopharma development through Corporate Development Initiative
Simulations Plus Reports Third Quarter Fiscal 2025 Financial Results
Updated full-year revenue guidance of between $76 to $80 million and adjusted diluted EPS of $0.93 to $1.06
Physiologically Based Pharmacokinetic Modeling and Mechanistic In Vitro-In Vivo Correlation for Long-Acting Injectable Suspension
Long acting injectable (LAI) suspensions demonstrate extended release by forming depots at the injection site (subcutaneous or intramuscular), from which poorly soluble drugs are slowly dissolved and absorbed into the systemic circulation
When Mechanistic IVIVC Falls Short: The Case for IVIVR in Oral Drug Delivery
Traditional IVIVC is robust for ER formulations where dissolution is rate limiting.
Prediction of Monoclonal Antibody Pharmacokinetics in Pediatric Populations Using PBPK Modeling and Simulation
Accurately determining pediatric dosing is essential prior to initiating clinical trials or administering medications in routine clinical settings.
Optimizing Extended-release Formulation of l-tetrahydropalmatine Based on In Vivo Outcomes Using Integrated Modeling Approaches
l-Tetrahydropalmatine (l-THP) is a promising drug candidate for addiction treatment and needs to be delivered in extended-release dosage forms for safety and efficiency.
Structure-Based Screening of Small-Molecule Interleukin-23 Inhibitors Inspired by Monoclonal Antibody Interactions
Interleukin-23 (IL-23) is a key driver of chronic inflammatory diseases, yet current therapies rely on costly monoclonal antibodies.
Thriving in the GenAI Era: A Guide for Scientists
In systems biology, we often speak of emergence—how complex systems yield behaviors not apparent from their individual parts.
Simulations Plus Announces Preliminary Third Quarter Fiscal 2025 Revenue
Updates fiscal 2025 revenue guidance range
Third quarter fiscal 2025 full results to be released on July 2, 2025, with conference call at 5 p.m. ET
Simulations Plus Announces Preliminary Third Quarter Fiscal 2025 Revenue
Updates fiscal 2025 revenue guidance range
Third quarter fiscal 2025 full results to be released on July 2, 2025, with conference call at 5 p.m. ET
Reversal of a Synthetic Opioid Overdose: Insights From a Validated Translational Model
Synthetic opioids are linked to >90 % of opioid overdose deaths in the United States.
Solid-State Evaluation of a Newly Emerged Polymorph for Early-Stage Pharmaceutical Development
This work presents the solid-state evaluation of a new polymorph (Form M) discovered during the early-stage pharmaceutical development of a new chemical entity GDC-6599.
Establishing Virtual Bioequivalence and Bio-related Dissolution Specifications for Naproxen Using Physiologically Based Pharmacokinetic Modeling and in vitro Biorelevant Dissolution Testing
The aim of the present study was to assess the accuracy of the PBPK model in predicting the pharmacokinetic behavior of weakly acidic BCS class II drugs in humans through a multipronged approach of in vitro dissolution, in vivo studies, and in silico simulations.
Utilizing Metabolism-Based Structure-Activity Relationships and Biokinetic Modeling for Toxicological Evaluation: A Case Study on L-menthyl D-Lactate
Structure activity relationship (SAR) based read across uses existing toxicity data from an analog to predict the toxicity of a target chemical.
![Absorption, Distribution, Metabolism, and Excretion of [14C]SHEN211, a Nonpeptidic Small-Molecule 3CLpro Inhibitor, in Rats](https://www.simulations-plus.com/wp-content/uploads/ChatGPT-Image-Jul-15-2025-at-03_34_17-PM-1200x1024.jpg)
Absorption, Distribution, Metabolism, and Excretion of [14C]SHEN211, a Nonpeptidic Small-Molecule 3CLpro Inhibitor, in Rats
SHEN211 is a selective 3-chymotrypsin-like protease inhibitor that can protect against severe acute respiratory syndrome coronavirus 2.
Tissue Distribution and Pharmacokinetic Characteristics of Aztreonam Based on Multi-Species PBPK Model
As a monocyclic β-lactam antibiotic, aztreonam has regained attention recently because combining it with β-lactamase inhibitors helps fight drug-resistant bacteria.
ADMET Predictor® 13 Product Brochure
Proven algorithms. Premium data. Predictions you can rely on.
How to Improve Your Drug Candidate Quality Without Adding New Steps to Your Program
As every researcher in early development knows, there is constant pressure to identify high-quality drug candidates—while also increasing the speed and efficiency of the discovery process.